These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28676644)

  • 21. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K; Takigawa N; Ito S; Kashihara H; Ichihara E; Yasuda T; Shimizu K; Tanimoto M; Kiura K
    Mol Cancer Ther; 2011 Sep; 10(9):1720-7. PubMed ID: 21712475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
    Coco S; Truini A; Alama A; Dal Bello MG; Venè R; Garuti A; Carminati E; Rijavec E; Genova C; Barletta G; Sini C; Ballestrero A; Boccardo F; Grossi F
    Target Oncol; 2015 Sep; 10(3):393-404. PubMed ID: 25341405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway.
    Yamazaki S; Higuchi Y; Ishibashi M; Hashimoto H; Yasunaga M; Matsumura Y; Tsuchihara K; Tsuboi M; Goto K; Ochiai A; Ishii G
    Cancer Sci; 2018 Jun; 109(6):2063-2073. PubMed ID: 29701925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration.
    Pal S; Kabeer SW; Tikoo K
    Toxicol Appl Pharmacol; 2024 Apr; 485():116907. PubMed ID: 38521369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
    Wang YC; Wu DW; Wu TC; Wang L; Chen CY; Lee H
    Int J Biol Sci; 2018; 14(1):47-56. PubMed ID: 29483824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways.
    Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P
    Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
    Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A hybrid of coumarin and phenylsulfonylfuroxan induces caspase-dependent apoptosis and cytoprotective autophagy in lung adenocarcinoma cells.
    Wang Q; Guo Y; Jiang S; Dong M; Kuerban K; Li J; Feng M; Chen Y; Ye L
    Phytomedicine; 2018 Jan; 39():160-167. PubMed ID: 29433677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer.
    Ma R; Li X; Liu H; Jiang R; Yang M; Zhang M; Wang Y; Zhao Y; Li H
    Cancer Biol Ther; 2019; 20(9):1206-1212. PubMed ID: 31092103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
    Biochem Biophys Res Commun; 2012 Jul; 423(4):667-71. PubMed ID: 22695117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production.
    Fan J; Zhang X; Wang S; Chen W; Li Y; Zeng X; Wang Y; Luan J; Li L; Wang Z; Sun X; Shen B; Ju D
    Cell Death Dis; 2019 Aug; 10(9):626. PubMed ID: 31427566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
    Li B; Yuan Z; Jiang J; Rao Y
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.
    Kim JH; Nam B; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Chang EJ; Koh JS; Song JS; Yoon S; Lee JC; Rho JK; Son J
    Cancer Res; 2018 Aug; 78(16):4482-4496. PubMed ID: 29945964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
    Kudo K; Ohashi K; Makimoto G; Higo H; Kato Y; Kayatani H; Kurata Y; Takami Y; Minami D; Ninomiya T; Kubo T; Ichihara E; Sato A; Hotta K; Yoshino T; Tanimoto M; Kiura K
    Mol Oncol; 2017 Jun; 11(6):670-681. PubMed ID: 28388009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
    Pirazzoli V; Nebhan C; Song X; Wurtz A; Walther Z; Cai G; Zhao Z; Jia P; de Stanchina E; Shapiro EM; Gale M; Yin R; Horn L; Carbone DP; Stephens PJ; Miller V; Gettinger S; Pao W; Politi K
    Cell Rep; 2014 May; 7(4):999-1008. PubMed ID: 24813888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
    Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.